According to Euro data, a total of 55 investment and financing events were disclosed yesterday, involving 33 domestic enterprises and 22 foreign enterprises, with a total financing of about 13.501 billion yuan.
Among them, the medical and health sector disclosed a total of 11 investment and financing events, involving 6 domestic enterprises and 5 foreign enterprises, with a total financing of about 2.41 billion yuan.
In the field of medical and health care in China, a total of 1 enterprise was acquired and 5 enterprises were invested, with a total financing of about 750 million yuan.
1. Cambodia-China Biology is acquired by China's environmental protection technology, the former is headquartered in the Hong Kong Special Administrative region of China, is a biological cell storage service provider
two。 Kangyuanbo has completed tens of millions of RMB A + round financing, with Yuanhui Venture Capital, Shan Lan Capital, Yi Huicheng and Matrix Partners as the investors. the amount of financing this round ranks in the top 50% of all A+ round financing this year. Kangyuan Bochuang, headquartered in Beijing, China, is a research and development company of antineoplastic drugs.
3.Ablaze Pharmaceuticals completed US $75 million in round A financing, with investors such as Shangli Capital, Dingfeng Capital, Vivo Capital, Samsara BioCapital, venBio Partners, Nan Fung Life Sciences and Venrock Healthcare Capital Partners. The current round ranks in the top 5% of all round A financing this year. Ablaze Pharmaceuticals, headquartered in Shanghai, China, is a developer of therapeutic radiopharmaceuticals.
4. Weiyan Medical has completed hundreds of millions of RMB A round financing, and the investor is Lianhe Investment, which ranks in the top 50% of all A round financing this year. Headquartered in Beijing, China, Weiyan Medicine is a research and development company of clinical infection pathogen diagnosis products.
5. Yuansheng has completed hundreds of millions of RMB Pre-A round financing, with Quanchuang Capital and Qianji Capital as the investors. This round ranks in the top 10% of all Pre-A round financing this year. Yuanyin Biology, headquartered in Beijing, China, is a vaccine developer.
6. Jingrui completed 50 million yuan of angel round financing, invested by Yuansheng Venture Capital and QiMing Venture Partners, and this round ranks in the top 10% of all angel round financing this year. Jingrui Biology, headquartered in Jiangsu Province, China, is a medical device manufacturer.
A total of 5 foreign enterprises in the field of medical and health care have been invested, with a total financing of about 1.66 billion yuan.
1.aTyr Pharma received $86.3 million in strategic investment, with the current round ranking in the top 20 per cent of all strategic investments this year. ATyr Pharma, headquartered in the United States, is an American manufacturer of biological agents.
2.Algamed Therapeutics, which is headquartered in Israel and is an Israeli biotechnology service provider, received a strategic investment of US $1.76 million.
3.Quell Therapeutics completed US $156 million in round B financing, with investors such as Tekla Capital Management, Ridgeback Capital, Jeito Capital, British Patient Capital, Point72, Monashee Investment Management, SV Health Investors, Janus Henderson Investors and Fidelity Management and Research Company. The current round ranks among the top 5 per cent of all round B financing this year. Quell Therapeutics, headquartered in the UK, is a British cell therapy company
4.PayZen completed US $15 million in round A financing, with investors SignalFire, Link Ventures, Picus Capital, 7Wire Ventures and Viola Ventures. The current round ranks in the top 50% of all round A financing this year. PayZen, headquartered in the United States, is an American medical financial technology service provider.
5.DeinPflege.de completed the seed round financing, invested by APX, the company is headquartered in Germany, is a German health management platform.
As of November 29, 2021, a total of 1882 investment and financing events have taken place in the global health care sector this year, with a total financing amount of about 980.147 billion yuan. A total of 1151 investment and financing events occurred in the domestic medical and health field this year, with a total financing amount of about 265.051 billion yuan.
注：
1. The field of health care refers to the health care industry in the 100 million euro data industry classification.
two。 According to the above-mentioned statistics of financing amount, fuzzy finance and undisclosed amount have been converted into estimated values in accordance with certain rules, and uniformly converted into RMB.
To review the investment and financing situation in health care sector on November 26th, please click on the Health Care Investment and financing Daily (November 26th): Lotus Pharmaceutical was acquired by Aztiq and Innobic
Euro data is committed to providing useful industry insight tools and effective business decision-making tools for organizations that can lead the development of technology and industry. For more detailed investment and financing data in more areas, you are welcome to visit Euro data.